Arbele is a biotech and biopharmaceutical company focused on invention of proprietary immunotherapeutic platforms to accelerate the development of innovative "first-in-class" antibody-based biologics to treat gastrointestinal cancers, in particular, stomach, pancreas, colon, bile duct and liver, which remain of high mortality and with limited treatment options. The company is founded in 2016 by reputable academic and industry veterans with R&D and offices in HK, Guangzhou, Sydney and Seattle. Targeted markets cover the Greater China, APAC and North America.